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alternative splicing in colon
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Abstract
Background: The Mnk2 kinase, encoded by MKNK2 gene, plays critical roles in MAPK signaling and was involved in
oncogenesis. Human MKNK2 pre-mRNA can be alternatively spliced into two splicing isoforms, the MKNK2a and
MKNK2b, thus yielding Mnk2a and Mnk2b proteins with different domains. The involvement of Mnk2 alternative
splicing in colon cancer has been implicated based on RNA-sequencing data from TCGA database. This study
aimed at investigating the upstream modulators and clinical relevance of Mnk2 alternative splicing in colon
adenocarcinoma (CAC).
Methods: PCR, western blotting and immunohistochemistry (IHC) were performed to assess the expression of
Mnk2 and upstream proteins in CAC. The function of Mnk2 and its regulators were demonstrated in different CAC
cell lines as well as in xenograft models. Two independent cohorts of CAC patients were used to reveal the clinical
significance of MKNK2 alternative splicing.
Results: Comparing with adjacent nontumorous tissue, CAC specimen showed a decreased MKNK2a level and an
increased MKNK2b level, which were correlated with KRAS mutation and tumor size. The SRSF1 (serine/arginine-rich
splicing factor 1) was further confirmed to be the major splicing factor targeting MKNK2 in CAC cells. Higher
expression of SRPK1/2 or decreased activity of PP1α were responsible for enhancing SRSF1 phosphorylation and
nucleus translocation, subsequently resulted in a switch of MKNK2 alternative splicing.
Conclusions: Our data showed that phosphorylation and subcellular localization of SRSF1 were balanced by SRPK1/
2 and PP1α in CAC cells. High nucleus SRSF1 promoted MKNK2 splicing into MKNK2b instead of MNK2a,
consequently enhanced tumor proliferation.
Keywords: Alternative splicing, Colon adenocarcinoma, MKNK2, SRSF1, SRPK1/2
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: xuzekuan@njmu.edu.cn; xuyunfei1988@126.com
1Department of General Surgery, The First Affiliated Hospital of Nanjing
Medical University, 300 Guangzhou Road, Nanjing 210029, China
3Department of General Surgery, Qilu Hospital of Shandong University, Jinan
250012, China
Full list of author information is available at the end of the article
Liu et al. Journal of Experimental & Clinical Cancer Research           (2021) 40:75 
https://doi.org/10.1186/s13046-021-01877-y
Background
Colorectal cancer ranks the third on both malignant
morbidity and cancer-related deaths worldwide [1]. Ap-
proximately 20% of colorectal cancer patients were diag-
nosed at an extensive-stage with distant distribution, and
the 5-year survival rate is less than 15% [2]. As the most
common histological subtype, colon adenocarcinoma
(CAC) can be treated with surgical resection, adjuvant
chemotherapy, and radiation treatment. Unfortunately,
molecular understanding of CAC progression remains
limited although its incidence and mortality rates have
been declined during the past decades [3].
Numerous well-known kinase networks are considered
to play roles in CAC pathogenesis, such as EGFR,
MAPKs, c-Src, et al. The MAP kinase-interacting serine/
threonine-protein kinases (Mnks), downstream of
MAPKs, are protein kinases that can phosphorylate
eIF4E and enhance oncogenic mRNA translation [4].
There are two members of Mnk family in human cells:
Mnk1 and Mnk2. We have previously reported the clin-
ical significance of Mnk1 in epithelial ovarian cancer [5].
Mnk2 has also been reported to be involved in malig-
nancies such as prostate cancer and lung cancer [6, 7].
Mnk2a and Mnk2b are two protein isoforms that de-
rived from the MKNK2 pre-mRNA by alternative spli-
cing, namely MKNK2a and MKNK2b, respectively [8].
Mnk2a contains a MAPK-binding site in its C-terminus
while Mnk2b lacks it [9]. The specific role of Mnk2a
seems ambiguous in tumorigenesis. On one hand, hyper-
activation of Mnk2a can phosphorylate eIF4E thus exerts
oncogenic effects [9]. One the other hand, Mnk2a dir-
ectly interacts and phosphorylates p38α -MAPK, subse-
quently inducing cell death and suppressing Ras-induced
transformation [10]. In contrast, Mnk2b is generally rec-
ognized as a pro-oncogenic kinase due to its deficiency
in binding p38α -MAPK but reserves capacity of phos-
phorylating eIF4E [10].
According to TCGA database, the MKNK2a/MKNK2b
ratio was reported to be downregulated in CAC tissues
compared with nontumorous colon tissues [10], however
its clinical significance and upstream regulators remain
unknown. Here we discovered that SRSF1 (Serine and
Arginine Rich Splicing Factor 1), an essential sequence
specific splicing factor involved in pre-mRNA splicing, is
the predominant splicing factor that promotes synthesis
of MKNK2b instead of MKNK2a. Interestingly, SRSF1-
guided MKNK2a-MKNK2b switch is dependent on its
phosphorylation and subsequent nucleus transportation.
Our data further revealed the antergic effects of SRPK1/
2 (SR-specific protein kinase) and protein phosphatase
1α (PP1α) on directly modulating SRSF1 phosphoryl-
ation. Besides, SRPK1/2 and nucleus SRSF1 were verified
to be independent prognostic factors for the clinical out-
come of CAC patients from two retrospective cohorts.
Finally, the tumor-related role of SRPK1/2, SRSF1,
Mnk2b, and PP1α were validated in CAC cell lines as
well as in xenograft models.
Methods
Cells and reagents
Human CAC cell lines including Caco-2, HT-29, HCT-
116, SW480 and SW620 were purchased from the
American Type Culture Collection (ATCC, Manassas,
VA, USA). Nontumorous NCM460 colon epithelial cells
were obtained from Jennio Biotechnology (Guangzhou,
China). Cells were cultured in DMEM supplemented
with 10% fetal bovine serum (FBS) and 1% penicillin/
streptomycin under 5% CO2 at 37 °C atmosphere. The
chemicals used in our study were listed in Supplemen-
tary Table S6.
DNA constructs, siRNAs, shRNAs
pCDNA3.1-vector was obtained from Invitrogen. Full-
length of KRAS-G12V cDNA was cut from pBabe K-Ras
12 V vector (Cat. #12544, Addgene) and cloned into
pcDNA3.1-vector (Invitrogen) via BamH1 and Xba1 re-
striction sites, thus generating the pCDNA3.1-RAS-




PP1α-WT, pCDNA3.1-PP1α-T320A, and pCDNA3.1-
PP1α-H125A were generated by GenePharma (Shanghai,
China). The siRNAs and shRNAs were listed in Supple-
mentary Table S6.
Transient transfections were conducted by using Lipo-
fectamine3000 Transfection Reagent (Cat. # L3000015,
Thermo Fisher Scientific, Pittsburgh, PA, USA) accord-
ing to the manufacturer’s instructions. Puromycin was
used to select and maintain stable overexpression cells.
Lentivirus infection of SRPK1 and SPRK2 shRNAs were
conducted as previously described [11].
Patients and tissue samples
Two independent cohorts of patients were retrospect-
ively enrolled in this study. The primary cohort enrolled
32 CAC patients who underwent surgical treatment in
Qilu Hospital of Shandong University (Jinan, China)
from 2016 to 2017. The fresh-resected carcinoma tissues
and paired adjacent nontumorous colon tissues were all
frozen in liquid-nitrogen until experimental test. The
validation cohort comprised of 100 CAC cases that
underwent tumor resection in 2007, and the tissue speci-
mens were formalin-fixed paraffin-embedded (#HCo-
lA180Su17, Shanghai Outdo Biotech, Shanghai, China).
The patients in validation cohort were followed up until
July 2015 (ranging 2–97months). All the patients in pri-
mary cohort and validation cohort underwent R0
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resection and classified with TNM stage I-IIIC at the
time of surgical intervention according to the 7th AJCC/
UICC TNM classification system. None of the patients
in the two cohorts received any adjunctive therapy be-
fore tissue sample collection. The clinicopathological
characteristics of the patients in two cohorts were sum-
marized in Supplemental Table S1 and Supplemental
Table S3, respectively. Informed consents were obtained
from all patients or immediate relatives. All experiments
were approved and supervised by the Ethics Committee
of Qilu Hospital of Shandong University.
Real-time PCR (RT-PCR) and real-time quantitative PCR
(RT-qPCR)
Paired tumor and nontumorous specimens from primary
cohort were subjected for RNA isolation and RT-qPCR
using GAPDH as internal control. Briefly, total RNA was
extracted from tissues and cells using TRIzol reagent.
RNA was reversely transcribed into cDNA by Prime-
Script RT Master Mix (TaKaRa, Kyoto, Japan). Quantita-
tive polymerase chain reaction (qPCR) was conducted
with SYBR Premix Ex Taq II kits (TaKaRa, Kyoto, Japan)
as described before [12]. RT-PCR was performed using
the one step RT-PCR kit (QIAGEN) following the man-
ufacturer’s protocol. The primers used for RT-PCR and
RT-qPCR were listed in Supplemental Table S6.
Cell proliferation and colony formation
The proliferation assay colony formation assay were con-
ducted as previously described [13, 14]. Proliferation
capacity was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyl-2H-tetrazolium bromide (MTT) assays at
designated time points (6 h, 24 h, 48 h, 72 h, 96 h). Col-
onies were tested after incubation for 10 days in DMEM.
RNA-binding protein immunoprecipitation (RIP)
The RIP assay was conducted by using an RNA-Binding
Protein Immunoprecipitation Kit (Millipore) according
to the manufacture’s procedure. The binding between
the SRSF1 protein and MKNK2a/2b-mRNA was deter-
mined by RT-PCR and Western blotting of immunopre-
cipitated mixture.
Sample lysis and immunoblotting
Tissue samples or cultured cells were lysed using RIPA
lysis buffer (Cat. #P0013, Beyotime, Beijing, China) con-
taining protease and phosphatase inhibitors for total
protein test. For nucleus isolation, cells were processed
using the Nucleus and Cytosol Protein Extraction Kit
(Cat. #P0027, Beyotime) according to the manufacture’s
instruction. The immunoblotting was conducted as de-
scribed previously [14]. The antibodies used in our study
were listed in Supplementary Table S6 at 1:1000
dilution.
Immunohistochemical (IHC) staining
The IHC staining was performed as described before
[14] using anti-SRSF1, anti-SRPK1, anti-SRPK2, anti-
PP1α, anti-PP1α-p-Thr320 antibodies (Table S6) at 1:
300 dilution. The staining results were semi-quantified
by multiplying the positive percentage score (0, no posi-
tive stained cells; 1, 0–25% positive; 2, 26–50% positive;
3, 51–75% positive; 4, 76–100% positive) and staining in-
tensity score (0, negative staining; 1, slightly yellow; 2,
dark yellow; 3, yellow brown), ranging 0–12. As for the
quantification of SRSF1 staining, the nucleus staining
and cytosol staining were scored separately. Either the
nucleus staining or the cytosol staining were scored as
0–12 as described above. The cut-off of IHC scores were
obtained by using receiver operating characteristic
(ROC) curves to distinguish high- or low-expression
groups.
Immunoprecipitation
Transfected cells were harvested and lysed with RIPA
buffer. After protein quantification using the BCA kit
(Thermo Fisher Scientific), equal amount of lysates were
incubated with HA agarose beads overnight an 4 °C. The
immunoprecipitated mixture were subjected to Western
blotting after washing out the nonspecific bindings with
RIPA buffer.
GST-pull down
The purified GST protein was obtained from Prof. Jin-
peng Sun in Shandong University (Jinan, China). The
purified GST-tagged SRPK1 and GST-tagged SRPK2
proteins were purchased from Novus Biologicals (CO,
USA). The His-SRSF1 protein was purchased from Cre-
ative Biomart (NY, USA). The GST-pull down assay was
conducted as described before using GST agarose beads
[15].
In vitro phosphorylation test
Purified SRPK1 or SRPK2 proteins were incubated with
SRSF1 proteins in kinase reaction buffer (25 mM Tris,
pH 7.5, with 10mM MgCl2, 2 mM DTT, 5 mM β-
Glycerolphosphate, 0.1 mM Na3VO4, and 2mM EGTA)
containing 20 μM ATP for 30min at 37 °C water bath.
Reactions were then quenched by adding SDS loading
buffer and subjected to western blot assay.
Mice model and xenograft
Transfected SW480 cells (4 × 106) were subcutaneously
injected into six-week male Balb/c nude mice. Each
group contained 5 mice. Tumor size was measured every
5 days using the following formula: V = (length×width2)/
2. The mice were sacrificed on the 21st day after injec-
tion, and the xenograft tumors were removed and
weighed as described before [13]. The Animal Welfare
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Committee of Shandong University approved all proce-
dures involving animals.
Statistics
Data are presented as the mean ± standard deviation
(SD). Statistical analyses were conducted using SPSS
20.0 Software. Correlations between mRNAs were ana-
lyzed using Spearman correlation test. Correlations be-
tween proteins and patients’ characteristics were
analyzed using Chi-square test. Overall survival (OS)
was assessed using the Kaplan-Meier method and signifi-
cance was analyzed using the log-rank test. Multivariate
cox regression analyses were carried out to identify inde-
pendent prognostic factors. For the cellular and xeno-
graft data, the difference between two groups was tested
using Student’s t-test, while One-way ANOVA analysis
was used to compare data among more than two groups.
A value of P < 0.05 indicated a statistically significant
result.
Results
MKNK2 alternative splicing is altered in CAC tissues and
affected by KRAS mutation
MKNK2 can be alternatively spliced to MKNK2a and
MKNK2b mRNAs and consequently translated into two
protein isoforms: Mnk2a and Mnk2b (Fig. 1a). By ana-
lyzing the mRNAs level of MKNK2 isoforms in 32 paired
tissues (Table S1), we found that MKNK2a was down-
regulated in CAC tumor tissues while MKNK2b was up-
regulated (Fig. 1b). Mutations of KRAS and TP53 are the
most well-characterized onco-driver of CAC, and we
next investigated whether they have effects on MKNK2
alternative splicing (Fig. 2c). Although TP53 seemed to
have no impact on MKNK2 mRNA levels, MKNK2a
splicing was inhibited while MKNK2b was remarkably
upregulated in KRAS-mutated CAC samples. Therefore,
we enrolled both KRAS-WT cells (Caco-2 and HT-29)
and KRAS-mutated cells (HCT-116 and SW480) to con-
duct cellular validation. Comparing with Caco-2 and
HT-29 cells, HCT-116 and SW480 cells showed lower
MKNK2a but higher MKNK2b mRNA levels (Fig. 1d).
Furthermore, transfecting Caco-2/HT-29 cells with
KRAS-G12V plasmids significantly altered the predomin-
ant MKNK2 isoform from MKNK2a to MKNK2b (Fig.
1e), indicating that KRAS can affect MKNK2 alternative
splicing. We next aimed to seek whether the KRAS-
G12V-induced MKNK2b was resulted from increased
RNA synthesis or decreased RNA degradation using
NCM460 cells. Actinomycin D is a potent inhibitor that
can inhibit poly(A)RNA synthesis in a dose-dependent
manner [16]. According to our data, actinomycin D
treatment significantly attenuated the KRAS-G12V-in-
duced MKNK2b expression at 20 nM or higher concen-
trations (Fig. 1f), implying this MKNK2b alteration was
correlated with RNA synthesis instead of RNA degrad-
ation. Interestingly, MKNK2a and MKNK2b showed op-
posite effects on KRAS-G12V-induced colony formation
of NCM460 cells (Fig. 1g), indicating their distinct roles
in modulating tumor development.
MKNK2 alternative splicing is correlated with tumor
growth instead of LN metastasis
Additionally, MKNK2a was relatively lower in tumors
with larger size while MKNK2b was higher in larger
CAC tissues (Fig. 1h). Spearman correlation test showed
that tumor diameter was negatively correlated to
MKNK2a level and positively correlated to MKNK2b
level (Fig. S1A, S1B). Apparently, the MKNK2a/
MKNK2b ratio was decreased in tumor specimens with
larger diameter (Fig. S1C). In contrast, we didn’t identify
any significant correlation between MKNK2 mRNA
levels with lymph node (LN) metastasis (Figure S1D), in-
dicating MKNK2 may have little effect on modulating
tumor invasion. Since we showed that MKNK2 alterna-
tive splicing is closely correlated with KRAS mutation,
we chose HCT-116 and SW480 cell for following cellu-
lar tests in this study. Although transfection of Mnk2a
had no obvious effect on CAC cell proliferation (Fig. 1i)
nor colony formation (Fig. 1j), overexpressing Mnk2b
significantly enhanced cell proliferation capacity. Both
our clinical and cellular findings suggested a novel
tumor-promoting role of Mnk2b on CAC progression.
Nucleus SRSF1 is closely correlated with MKNK2
alternative splicing in tumor tissues
Since KRAS is not a splicing factor and is less possible
for directly regulating MKNK2 alternative splicing, we
next aimed to figure out the upstream splicing factors
targeting MKNK2. Serine/arginine-rich splicing factors
(SRSFs) are the major splicing factors that regulate alter-
native splicing process in mammalian cells [17]. By test-
ing the mRNA levels of SRSF family members, we found
that SRSF2 showed a positive relationship with MKNK2b
level. In contrast, SRSF3, SRSF4 and SRSF9 showed
negative correlations with MKNK2a level (Figure S2,
Table S2). However, only SRSF1 was negatively corre-
lated with MKNK2a and positively correlated with
MKNK2b simultaneously, indicating its predominant
role on modulating MKNK2a-MKNK2b switch in CAC
tissues (Fig. 2a, b). Moreover, RNA-immunoprecipitation
results confirmed the interaction between SRSF1 protein
and MKNK2a/2b-mRNA in SW480 cells (Fig. 2c).
Therefore, we further investigated whether SRSF1 par-
ticipate in CAC progression via MKNK2a-MKNK2b
switch. RT-qPCR and immunoblotting data showed that
SRSF1 was upregulated in tumor tissues compared with
adjacent nontumorous tissues on both RNA and protein
levels (Fig. 2d, e). Interestingly, IHC data identified a
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diffused staining of SRSF1 protein in both nucleus and
cytoplasm (Fig. 2f). To better evaluate the alteration of
SRSF1 in CAC tissues, we separately assessed its
expression in nucleus or cytoplasm. No statistical differ-
ence was observed between tumor tissues and adjacent
tissues regarding to cytoplasm-SRSF1. Nevertheless,
Fig. 1 Alternative splicing of MKNK2 in CAC tissues is correlated with oncogenic characteristics. a The schematic model of Mnk2 isoforms.
MKNK2a and MKNK2b possess different exon 13. The C-terminus of Mnk2a is translated from exon13a and exon13b, therefore contains a MAPK
binding motif and can bind with MAPK members. In contrast, Mnk2b is generated by an alternative 3′ splicing site between exon13a and
exon13b, leading to the absence of MAPK binding motif. b RNA levels of MKNK2a and MKNK2b were tested via RT-qPCR in 32 pairs of CAC tumor
tissues and adjacent nontumorous tissues. P value was based on paired Student’s t-test. c Clinical significance of MKNK2 alternative splicing was
evaluated by analyzing its correlation with KRAS and TP53 mutations. d Expressing of MKNK2a and MKNK2b were tested in distinct CAC cell lines
via RT-PCR. Caco-2 and HT-29 cells are documented with wild type KRAS, while HCT-116 and SW480 cells with mutated-KRAS (G13D and G12V
mutation, respectively). e RAS-G12V transfecting resulted in decreased MKNK2a and increased MKNK2b in both Caco-2 and HT-29 cells. f
Actinomycin D (20 nM, 80 nM, 200 nM) was used to assess whether the RAS-G12V-induced upregulation of MKNK2b was caused by enhanced
RNA synthesis or attenuated RNA-damaging. Accordingly, Ras-G12V can enhance MKNK2a-MKNK2b switch while actinomycin D inhibited RNA
synthesis. g Colony formation assays revealed that RAS-G12V-induced oncogenic transformation was inhibited by Mnk2a while enhanced by
Mnk2b transfection. P value was based on unpaired Student’s t-test comparing with RAS-G12V group. (H) A lower MKNK2a level and a higher
MKNK2b level were found in tumors with larger size (n = 20) comparing with the smaller ones (n = 12). P value was based on unpaired Student’s
t-test. (I) MTT proliferation assays showed the oncogenic effect of Mnk2b on promoting tumor proliferation in both HCT-116 and SW480 cells. P
value was based on unpaired Student’s t-test comparing with cells transfected with pcDNA-vector. (J) Overexpressing Mnk2b enhanced colony
formation of the CAC cell line HCT-116 and SW480 cells. Colonies were counted after incubation for 10 days in DMEM. P value was based on
unpaired Student’s t-test comparing with cells transfected with pcDNA-vector
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CAC samples showed higher total SRSF1 and nucleus-
SRSF1 than nontumorous tissues (Fig. 2g). In addition,
both total SRSF1 and nucleus-SRSF1 were positively cor-
related to MKNK2b-mRNA level, while negatively corre-
lated to MKNK2a and MKNK2a/MKNK2b (Figure S3A,
S3B). In contrast, cytoplasm-SRSF1 showed no significant
correlation with MKNK2 alternative splicing (Figure S3C).
Using ROC method (Figure S3D), we next divided the pri-
mary cohort into subgroups based on SRSF1 levels in differ-
ent subcellular locations. Consistent with Spearman
correlation test, Chi-square results also revealed a significant
difference of MKNK2 alternative splicing between low
nucleus-SRSF1 and high nucleus-SRSF1 groups (Fig. 2h).
Similar results were obtained based on total SRSF1 expres-
sion but not cytoplasm-SRSF1 (Fig. 2h).
TNPO3-dependent nucleus transportation of SRSF1
determines MKNK2 alternative splicing and cell
proliferation
We set out to explore the possible effects of SRSF1 on
MKNK2 alternative splicing in CAC cells. Knockdown of
SRSF1 can significantly inhibit MKNK2a-MKNK2b
switch according to RT-PCR (Fig. 3a) and RT-qPCR data
(Fig. 3b), respectively. Of note, cell proliferation and col-
ony formation capacities were also attenuated by silen-
cing SRSF1 (Fig. 3c, d). On the other hand,
overexpressing SRSF1 resulted in MKNK2a-MKNK2b
switch and enhanced cell proliferation (Fig. 3e-h). Tak-
ing into consideration that only nucleus-SRSF1, instead
of cytoplasm-SRSF1, showed a significant correlation
with MKNK2 alternative splicing in CAC samples, we
Fig. 2 Correlation between nucleus SRSF1 location and MKNK2 alternative splicing. a SRSF1 level was tested by RT-qPCR in clinical CAC tissues
(n = 32), and its correlations with MKNK2 variants were analyzed by Spearman correlation test. b RNA levels of other well-known splicing factors
were also measured by RT-qPCR. Spearman correlation tests showed that only SRSF1 was significantly correlated with both MKNK2a and MKNK2b
levels, indicating its potential effect on MKNK2a-MKNK2b switch. c SW480 cells transfected with pcDNA-vector or SRSF1 constructs were subjected
to RNA-IP using anti-SRSF1 antibody in formaldehyde crosslinked nuclear extracts. The existence of SRSF1 protein and MKNK2-mRNA were tested
via Western blotting and RT-PCR, respectively. d The mRNA levels of SRSF1 in 32 paired CAC tissues and adjacent nontumorous tissues were
compared by RT-qPCR. P value was based on paired Student’s t-test. e Protein levels of SRSF1 in clinical specimens were also tested by western
blotting (upper panel), and 71.9% cases (23/32) showed increased SRSF1 in tumor tissues (lower panel). f Immunohistochemical staining
identified different subcellular location of SRSF1 in tissue specimens, including nucleus location and cytoplasm location. Scale bar: 100 μm. g
Differences of SRSF1 IHC scores between CAC and adjacent nontumorous tissues were represented by box plots (n = 32). Top and bottom box
edges represented the third and first quartile. Whiskers indicated highest and lowest score. P value was based on paired Student’s t-test. h By
classifying patients into different subgroups according to ROC curves (Fig. S3D), we found that tissues with higher nucleus SRSF1 level or total
SRSF1 level expressed more MKNK2b variant and showed a lower MKNK2a/2b ratio. In contrast, no statistical difference was observed based on
cytoplasm SRSF1 level. P value was calculated by unpaired Student’s t-test
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hypothesize that nucleus transportation is critical for
SRSF1-guided MKNK2a/MKNK2b switch. Previous studies
had revealed that transportin 3 (TNPO3) can assist nucleus
trafficking of SRSF members [18], thus we blocked the nu-
cleus transportation of SRSF1 by silencing TNPO3 (Figure
S3E). Accordingly, TNPO3-siRNA abolished the role of
SRSF1 on promoting MKNK2a-MKNK2b switch (Fig. 3e, f)
and resulted in attenuated cell proliferation (Fig. 3g, h).
SRPK1 and SRPK2 are positively correlated with MKNK2a-
MKNK2b switch and SRSF1 nucleus translocation
Since phosphorylation plays vital roles on intracellular
trafficking of SRSF proteins [19], we were interested to
identify the upstream kinases responsible for SRSF1 nu-
cleus transportation. CDC2-like kinase 1 (CLK1) and
SR-specific protein kinases (SRPKs) had been proved to
phosphorylate the RS domain of SRSF1 through in vitro
kinase assays [20]. Therefore, we tested the statistical
relevance between MKNK2a-MKNK2b switch and
CLK1, SRPK1, SRPK2, respectively. Correlation test re-
vealed that CLK1 has no significant correlation with
MKNK2 alternative splicing (Fig. S4A). In contrast, the
level of SRPK1 mRNA is positively correlated with
MKNK2b level, while negatively correlated with
MKNK2a level or MKNK2a/MKNK2b ratio (Figure
S4B). As for SRPK2, although no significance was
Fig. 3 Nucleus transportation of SRSF1 exerts oncogenic effect via upregulating MKNK2b level. a HCT-116 and SW480 cells were transfected with
either scrambled siRNA or siRNAs targeting SRSF1. The transfection efficiencies were verified by western blotting. The alterations of MKNK2
alternative splicing were tested by RT-PCR. b Quantitative PCR results further confirmed the role of SRSF1 on regulating MKNK2 alternative
splicing. P value was based on unpaired Student’s t-test comparing with scrambled group. c MTT and colony formation (d) assays demonstrated
that SRSF1-knockdown inhibited CAC cell proliferation. P value was based on unpaired Student’s t-test comparing with scrambled group. e
Western blot results showed that silencing TNPO3 downregulated nucleus SRSF1 level, indicating nucleus importing of SRSF1 was at least
partially depend on TNPO3. Moreover, RT-PCR data indicated that silencing TNPO3 attenuated the effect of SRSF1 on altering MKNK2 alternative
splicing. f Quantitative PCR results further verified the role of TNPO3-siRNA on attenuating SRSF1-induced MKNK2a-MKNK2b switch. P value was
based on unpaired Student’s t-test comparing with SRSF1 group. g MTT and colony formation (h) assays demonstrated that TNPO3-knockdown
attenuated the oncogenic effect of SRSF1 on CAC cell proliferation. P value was based on unpaired Student’s t-test comparing with SRSF1 group
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observed towards MKNK2a level, it showed a significant
correlation with MKNK2b (Fig. S4C). Besides, both
SRPK1 and SRPK2 mRNA levels were upregulated in
tumor tissues comparing with adjacent tissues in our
primary cohort (Fig. 4a). TCGA database also revealed
upregulated transcriptions of SRSF1 and SRPKs (Figure
S5). Moreover, SRPK1 as well as SRPK2 showed positive
correlations with nucleus-SRSF1 protein level (Fig 4b),
indicating that SRPKs may promote nucleus transloca-
tion of SRSF1. We next evaluated protein expression
level of SRPKs in primary cohort by immunoblotting.
Consistent with mRNA data, both SRPK1 and SRPK2
proteins were elevated in tumor tissues (Fig. 4c).
Prognostic effects of SRSF1, SRPK1, and SRPK2
The findings in primary cohort and TCGA database pro-
moted us to further investigate the prognostic signifi-
cance of SRSF1 and SRPKs by introducing another
independent validation cohort (n = 100). IHC experi-
ments were conducted to explore the protein expression
and localization. SRPK1 and SRPK2 were predominantly
localized in cytoplasm, while SRSF1 was stained in both
nucleus and cytoplasm (Fig. 4d). In accordance with pri-
mary cohort, CAC samples in validation cohort showed
higher nucleus localization of SRSF1 and higher expres-
sion of SRPK1/2 (Fig. 4e). Besides, patients with higher
SRPK1 or SRPK2 were characterized with higher
nucleus-SRSF1 level (Fig. 4f). Furthermore, higher
SRPK1 was observed in patients with larger tumor size
and advanced tumor stages (Table S3).
Kaplan-Meier survival analyses revealed that patients
with higher nucleus-SRSF1 had a poorer overall survival
(Fig. 4g). Higher SRPK1 or higher SRPK2 also indicated
unfavorable prognosis, respectively (Fig. 4h, i). Of note,
patients with both high SRPK1 and high SRPK2 showed
a lowest overall survival time comparing with other sub-
groups (Fig. 4j). Prognostic effects of other clinicopatho-
logical factors were also summarized, which
demonstrated the clinical significance of lymph node
metastasis and TNM stage (Fig. 4k, Table S4). Addition-
ally, multivariate analysis was performed to explore inde-
pendent prognostic variables (Fig. 4l, Table S5). Higher
nucleus-SRSF1, higher SRPK1/2, and advanced TNM
stage were all identified as independent risk factors of
CAC overall survival.
Restoration of Mnk2b reverses the anti-proliferation
effects of SRPK knockdown
The effect of SRPKs on CAC progression were validated
by cellular experiments. The nonspecific SRPK inhibitor,
SRPIN340, can significantly inhibit cell proliferation and
colony formation of CAC cells (Fig. 5a, b). After testing
the transfection efficiency of SRPK1-siRNAs and
SRPK2-siRNAs (Figure S6A, S6B), we knocked down the
two kinases in CAC cells and found that silencing either
SRPK1 or SRPK2 showed no statistically significant ef-
fect on cell proliferation. However, simultaneously
knockdown of both SRPK1 and SRPK2 remarkably at-
tenuated cell proliferation and colony formation (Fig. 5c,
d). Interestingly, overexpressing Mnk2b restored the cell
proliferation capacity of SRPK1/2-silenced cells (Figure
S6C-E). In contrast, SRPK1 and SRPK2 overexpression
enhanced cell proliferation while TNPO3-siRNA almost
abolished this effect (Figure S6F-H).
SRPK1 and SRPK2 regulate MKNK2 alternative splicing by
directly phosphorylating SRSF1 and promoting SRSF1
nucleus transportation
We also compared the effects of SRPK1/2 knockdown or
SRPK1/2 overexpression on SRSF1 phosphorylation, nu-
cleus shuttling, and MKNK2 alternative splicing in CAC
cell lines (Fig. 5e, f; Figure S7A-D). As expected, either
SRPK1-siRNA or SRPK2-siRNA significantly inhibited
SRSF1 phosphorylation and nucleus translocation. In
contrast, SRPK1 or SRPK2 overexpression upregulated
the phosphorylation and nucleus accumulation of
SRSF1. Besides, overexpressing SRPK1/2 led to an en-
hanced MKNK2a-MKNK2b switch, while silencing
SRPK1/2 showed opposite effects according to RT-PCR
and RT-qPCR results. To further investigate whether
kinase activity of SRPK1/2 were critical for SRSF1-
guided MKNK2 alternative splicing, we generated the
kinase-dead mutants SRPK1-K109A and SRPK2-K110A.
Either kinase-dead mutant or inhibitor SRPIN340 sig-
nificantly attenuated, if not abolished, the role of
SRPK1/2 on modulating SRSF1 phosphorylation, nucleus
transportation as well as downstream MKNK2 alterna-
tive splicing (Fig. 5g, h; Figure S7E-H). Moreover, immu-
noprecipitation data identified the intracellular
interaction between SRSF1 with SRPK1/2 (Fig. 5i).
Extracellular GST pull down assay was then conducted
and confirmed their direct binding activity (Fig. 5j). We
next investigate whether the interaction between
SRPK1/2 and SRSF1 is a kinase-substrate process. In
vitro phosphorylation test showed that both SRPK1 and
SRPK2 are capable of phosphorylating SRSF1, which can
be inhibited by SRPIN340 (Fig. 5k). Therefore, SRPK1
and SRPK2 may directly phosphorylate SRSF1 and pro-
mote it nucleus translocation, subsequently modulate
MKNK2 alternative splicing.
PP1α activity is downregulated in colon adenocarcinoma
tissues
It has been reported that PP1α is the major phosphatase
that dephosphorylates SRSF1 [21], thus we explored
whether PP1α is responsible for antagonizing SRPK1/2
during CAC development. To our surprise, no signifi-
cant difference of PPP1CA mRNA level was observed
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between tumor tissues and adjacent tissues (Fig. 6a).
Taking into consideration that the phosphatase activity
of PP1α is as important as its expression level, we next
tested whether the activity of PP1α was altered in CAC
tissues by testing its phosphorylation on T320 site,
which inhibits its catalyzation capacity. IHC data showed
cytoplasmic localization of both PP1α and pT320-PP1α
(Fig. 6b). Consistent with RT-qPCR data, PP1α protein
level showed no difference between tumor and adjacent
tissues. However, the pT320-PP1α level was upregulated
in tumor tissues, indicating a decreased PP1α activity
(Fig. 6c).
PP1α negatively modulates SRSF1 nucleus transportation,
MKNK2 alternative splicing, and tumor proliferation
Furthermore, patients with higher nucleus-SRSF1
showed higher pT320-PP1α level but not total PP1α
level (Fig. 6d; Figure S8A). Spearman correlation test
also revealed a positive correlation between pT320-PP1α
and nucleus-SRSF1 (Fig. 6e) while no correlation was
observed regarding total PP1α (Figure S8B). Similarly, al-
though no association was identified between total PP1α
and MKNK2 alternative splicing (Figure S8C), pT320-
PP1α was positively correlated to MKNK2a-MKNK2b
switch (Fig. 6f).
In addition, the constitutively active mutant of PP1α,
PP1α-T320A, significantly inhibited proliferation of
CAC cells (Fig. 6g-i). Cellular assays were then per-
formed to test crosstalk between PP1α and SRSF1 by
overexpressing constitutively active mutant (T320A) or
inactive mutant (H125A) of PP1α, respectively. We
found that either PP1α-WT or PP1α-T320A can de-
crease SRSF1 phosphorylation and nucleus translocation,
while PP1α-H125A showed opposite effects (Fig. 6j; Fig-
ure S8D). Consistently, PP1α-T320A inhibited
MKNK2a-MKNK2b switch while PP1α-H125A pro-
moted it (Fig. 6j; Figure S8D). The PP1α specific inhibi-
tor, tautomycetin, can efficiently block the effects of
PP1α-WT or PP1α -T320A on altering SRSF1 phosphor-
ylation, nucleus translocation and MKNK2 alternative
splicing (Fig. 6k; Figure S8E). Furthermore, we observed
similar findings on SW620 cells, the metastatic cell line
of SW480 (Figure S9). Therefore, we concluded that
PP1α can suppress CAC progression at least partially by
inhibiting SRSF1-guided MKNK2a-MKNK2b switch,
which is dependent on SRSF1 phosphorylation and nu-
cleus shuttling.
SRPKs and PP1α have opposite effects on modulating
MKNK2 alternative splicing and tumor growth in mice
model
Xenograft models were utilized to verify tumor-related
roles of SRPK1/2 and PP1α in vivo. SW480 cells that
stably overexpressed SRPK1&2 or PP1α, or stably si-
lenced SRPK1/2 with shRNAs were seeded subcutane-
ously in Balb/c nude mice. There was no statistical
difference among the groups on the aspects of body
weight nor food consumption (Fig. 7a, b). Among the
four groups, SRPK1&2-overexpressing group showed the
highest proliferation capacity and largest tumor size. In
contrast, PP1α-T320A group and sh-SRPK1/2 group
both showed impaired growth process comparing to
control group (Fig. 7b-e).
The mRNA levels of MKNK2a and MKNK2b in iso-
lated xenografts were further tested by RT-qPCR, which
revealed consistent results with cellular assays. On one
hand, SRPK1&2 downregulated MKNK2a splicing and
upregulated MKNK2b level. On the other hand, PP1α-
T320A or sh-SRPK1/2 attenuated MKNK2a-MKNK2b
switch (Fig. 7f). Proliferation index of xenografts was
also evaluated by calculating Ki-67 positive staining (Fig.
7g). As a result, SRPK1&2 group showed the highest Ki-
67 staining percentage, while PP1α-T320A group and
sh-SRPK1/2 group showed decreased Ki-67 level, which
is consistent with tumor growth curve (Fig. 7h). Taken
together, our data revealed an oncogenic role of SRPK1/
2 signaling in colon adenocarcinoma cells (Fig. 7i). In
nontumorous cell, MKNK2 pre-mRNA is predominantly
spliced into MKNK2a and translated to Mnk2a protein,
which exerts anti-tumor effects. In colon
(See figure on previous page.)
Fig. 4 Expression and prognostic role of SRPKs in CAC. a RNA levels of upstream kinases targeting splicing factors in paired clinical specimens
were tested by RT-qPCR (n = 32). P value was based on paired Student’s t-test. b Correlations between nucleus SRSF1 level and upstream kinases
were analyzed via Spearman correlation test (n = 32). The nucleus SRSF1 level was scored by the specific nucleus staining of SRSF1 (ranging 0–12)
without considering its cytosol staining. c Protein levels of SRPK1 and SRPK2 in paired clinical specimens were tested by western blotting (left
panel). After semi-quantified, we found that 75% cases (24/32) showed increased SRPK1 in tumor tissues (middle panel), and 71.9% cases (23/32)
exhibited increased SRPK2 (right panel). d Representative IHC results of SRSF1, SRPK1, and SRPK2 in specimens from validation cohort. Scale bar:
100 μm. e The different protein levels of SRPK1, SPRK2, and nucleus SRSF1 in validation cohort were exhibited by box plots according to IHC data.
P value was based on unpaired Student’s t-test. f Patients with both high-SRPK1 and high-SRPK2 levels exhibited the highest nucleus SRSF1 level,
while patients with low SRPK1 and low SRPK2 showed the lowest nucleus SRSF1 IHC score. P value was based on One-way ANOVA test. Kaplan-
Meier survival curves showed the clinical relevance of nucleus SRSF1 (g), SRPK1 (h), and SRPK2 (i) in validation cohort of CAC patients,
respectively. Furthermore, the higher expression of both SRPK1 and SRPK2 showed a more significant role on indicating poorer overall survival (j).
Forest plots summarized the significant prognostic factors by univariate (k) and multivariate (l) analyses, the corresponding data were
supplemented in Table S4 and Table S5. P value was calculated by log-rank test or Cox-regression test
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adenocarcinoma cells, SRSF1 is hyperphosphorylated
due to elevated SRPK1/2 and decreased PP1α activity,
resulting in SRSF1 nucleus shuttling. Nucleus SRSF1 ac-
cumulation finally leads to alterative splicing of MKNK2
pre-mRNA to MKNK2b and upregulated the Mnk2b
oncoprotein level (Fig. 7i).
Discussion
Alternative splicing expands the proteomic complexity by
generating splicing variants on mRNA level and encoded
distinct protein isoforms including kinases. In the present
study, we focused on MKNK2a and MKNK2b alternative
splicing, encoding Mnk2a and Mnk2b, respectively. Our
data revealed a downregulation of MKNK2a and an up-
regulation of MKNK2b in colon adenocarcinomas, which
is closely correlated with KRAS mutation. The hyper-
synthesis of MKNK2b is observed in samples with larger
tumor size, implying its role on promoting tumor prolifer-
ation. Maimon et al. had recently reported that Mnk2b is
deficient on activating p38-induced cell death pathway,
while maintaining its capacity of promoting eIF4E-
induced oncoprotein translation. In contrast, Mnk2a can
induce both oncogenesis as well as p38-MAPK stress
apoptosis pathway. Therefore, they elucidated down-
stream mechanism of how Mnk2a and Mnk2b exert op-
posite effects on tumor progression in Ras-activated cells
[10]. Consistently, our data also revealed a significant cor-
relation between MKNK2 splicing shift with KRAS muta-
tion in colon adenocarcinomas, while no obvious
association with TP53 was identified. Additionally, cell
lines possessing KRAS mutation showed a prevalence of
MKNK2a-MKNK2b switch in comparison with KRAS-
WT cell lines. Strikingly, KRAS-G12V transfection en-
hanced MKNK2b mRNA splicing even in nontumorous
colon epithelial cells, indicating an oncogenesis correlation
between KRAS mutation and MKNK2 alternative splicing.
According to the data reported by Maimon et al. [10],
oncogenic transformation caused by activated Ras can in-
duce MKNK2a-MKNK2b switch in breast cancer cells,
pancreatic cancer cells and in lung cancer cells. Further-
more, coexpressing Mnk2a inhibited the oncogenic
phenotype of Ras-transformed MCF-10A cells, indicating
that Mnk2a can block Ras-induced transformation [10].
Therefore, it is high likely that oncogenic Ras induces
tumor transformation at least partially through affecting
MKNK2a-MKNK2b switch. Another study by Maimon
et al. artificially induced a strong switch from MKNK2b to
MKNK2a by using designated oligonucleotides, resulting
in inhibited glioblastoma development and re-
sensitization to chemotherapy [22]. Their study provides
evidence on the therapeutic potential of manipulating
MKNK2 alternative splicing as a novel approach to treat
glioma. Our present results regarding MKNK2a-MKNK2b
switch in colon adenocarcinoma implicated that similar
intervention may be a novel direction for CAC treatment.
In addition, our RT-qPCR screening assay indi-
cated SRSF1 as a promising modulator targeting
MKNK2 alternative splicing, which was confirmed by
correlation test, RNA immunoprecipitation, and knock-
down assays. The findings on that nuclear SRSF1, instead
(See figure on previous page.)
Fig. 5 SRPKs promote SRSF1 phosphorylation, nucleus transportation, and downstream MKNK2 alternative splicing. a Treatment with SRPKs
inhibitor, SRPIN340, resulted in decreased proliferation of HCT-116 and SW480 cells. P value was based on unpaired Student’s t-test comparing
with mock group which was treated with DMSO. b Colony formation assay also demonstrated an anti-proliferation effect of SRPIN340 on CAC
cells, indicating the oncogenic role of SRPKs. P value was based on unpaired Student’s t-test comparing with mock group. c MTT and colony
formation (d) assays demonstrated that silencing either SRPK1 or SRPK2 may impair CAC proliferation, although the statistical difference was not
significant. Knockdown of both SRPK1 and SRPK2 can significantly inhibit CAC cell proliferation. P value was based on unpaired Student’s t-test
comparing with scrambled group. e Knockdown of either SRPK1 or SRPK2 attenuated phosphorylation of SRSF1 (p-SRSF1) and reduced nucleus
SRSF1 (N-SRSF1) level. RT-PCR results showed a positive correlation between MKNK2b and SRPKs. Furthermore, simultaneously knockdown of
SRPK1 and SRPK2 exhibited the most significant effects. Semi-quantification of immunoblotting results and corresponding RT-qPCR data were
shown in Supplementary Figure S7A-B. f Overexpressing SRPKs increased phosphorylation of SRSF1 and promoted its nucleus translocation
according to immunoblotting results. Semi-quantification of immunoblotting results and corresponding RT-qPCR data were shown in
Supplementary Figure S7C-D. g SRPIN340 treatment towards SRPK1-overexpressing cells abolished the effects above. Consistently, the kinase
dead (KD) mutant SRPK1-K109A, lost effects on modulating SRSF1 phosphorylation, subcellular location, and MKNK2a-MKNK2b switch. Semi-
quantification of immunoblotting results and corresponding RT-qPCR data were shown in Supplementary Figure S7E-F. h SRPIN340 treatment
towards SRPK2-overexpressing cells also abolished its effects on modulating SRSF1 phosphorylation, subcellular location, and MKNK2a-MKNK2b
switch. The KD mutant of SRPK2, namely SRPK2-K110A, showed similar effects with SRPIN340. Semi-quantification of immunoblotting results and
corresponding RT-qPCR data were shown in Supplementary Figure S7G-H. i SW480 cells were transfected with HA-tagged SRPK1 (pcDNA-SRPK1)
or HA-tagged SRPK2 (pcDNA-SRPK2) or pcDNA-vector constructs. After lysing cells and conducting immunoprecipitation assay with anti-HA
agarose, we found that SRPK1 and SRPK2 can interact with SRSF1 in CAC cells. j Purified GST-tagged SRPK1 or GST-SRPK2 proteins were
incubated with purified SRSF1 proteins in vitro using GST protein as negative control. GST pull-down assay demonstrated the direct interaction
between SRPK1/2 with SRSF1. The input was shown in upper panel. k The kinase activity of SRPK1/2 targeting SRSF1 was tested by in vitro kinase
assay. Purified SRSF1 was incubated with GST-SRPK1 or GST-SRPK2 with/without SRPIN340 (10 μM) as described in the Method section. Reaction
products were separated via SDS-PAGE and analyzed by western blotting. Phosphorylation of SRSF1 in reaction products was semi-quantified
after normalized by total SRSF1 (lower panel). The data showed that both SRPK1 and SRPK2 can directly phosphorylate SRSF1, which can be
inhibited by the inhibitor SRPIN340
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of cytoplastic SRSF1, was correlated with patients’
clinical outcomes promoted us to further explore the
upstream regulation mechanisms of SRSF1 subcellular
trafficking. Consistent with electron microscopy data
[23], we verified the critical role of TNPO3 on
importing SRSF1 into nucleus of colon adenocarcin-
oma cells. Further study showed that the tumor-
promoting role of SRSF1 can be significantly attenu-
ated by silencing TNPO3, confirming that only nu-
cleus SRSF1 exerts pro-oncogenic effects.
Post-translational modification has remained the focus
of protein function investigation during the past decades,
and phosphorylation is one of the most important modi-
fications which we focused on [24, 25]. Abnormal ex-
pression of kinases or phosphatases can result in
dysregulated phosphorylation events, leading to various
malignancies as we previously reported [14, 26]. It has
been reported that multisite phosphorylation of SRSF1 is
a prerequisite for its nucleus transportation [27, 28],
which is the key mechanism for its functional alternative
Fig. 6 PP1α activity is decreased in CAC tissues and correlates with SRSF1-dependent MKNK2 alternative splicing. a There was no statistical
difference of PPP1CA mRNA levels between tumor tissues and adjacent nontumorous tissues. P value was based on paired Student’s t-test (n =
32). b Representative IHC images showed the immunoreactivities of total PP1α and phosphorylated-PP1α (pT320-PP1α) in clinical specimens.
Scale bar: 100 μm. c Although no difference regarding total PP1α protein level was observed between tumor and adjacent tissues (left panel),
tumor tissues exhibited higher phosphorylation on T320 site (pT320-PP1α, right panel) based on IHC data. P value was based on paired Student’s
t-test (n = 32). d Tumor tissues with higher nucleus SRSF1 showed higher pT320-PP1α levels. P value was based on unpaired Student’s t-test. e
Spearman correlation test further confirmed a positive correlation between nucleus SRSF1 and pT320-PP1α levels. f Spearman correlation test
identified a negative correlation between pT320-PP1α and MKNK2a levels. In contrast, MKNK2b was positively correlated with pT320-PP1α level. g
Proliferation capacity of SW480 cells or HCT-116 cells (h) was impaired by overexpressing pcDNA-PP1α-T320A, a constitutively active PP1α
construct, as revealed by MTT assays. P value was based on unpaired Student’s t-test. i Colony formation assay was conducted for the cells
described in (g) and (h), further indicating that PP1α-T320A may attenuate CAC proliferation. j CAC cells were transfected with three different
PP1α constructs, including PP1α-WT, PP1α-T320A (constitutively active mutant), and PP1α-H125A (kinase-dead mutant) using pcDNA-vector as
control. The levels of phosphorylated SRSF1, nucleus SRSF1 were measured by western blotting, and the MKNK2 splicing were evaluated by RT-
PCR (lower panel). Semi-quantification of immunoblotting results and corresponding RT-qPCR data were shown in Supplementary Figure S8D. (K)
CAC cells were transfected with PP1α-WT or PP1α-T320A with/without tautomycetin treatment. The levels of phosphorylated SRSF1, nucleus
SRSF1 were measured by western blotting, and MKNK2 splicing were evaluated by RT-PCR (lower panel). Semi-quantification of immunoblotting
results and corresponding RT-qPCR data were shown in Supplementary Figure S8E
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splicing. Therefore, we next aimed to investigate the up-
stream kinase and phosphatase which controls SRSF1
phosphorylation. Three major kinases had been reported
to phosphorylate SRSF1 including SRPK1, SRPK2, and
CLK1 [19, 20]. Considering that enzyme-substrate rela-
tionship can be difference in various cell types, we ini-
tially explored whether those kinases could affect SRSF1
nucleus translocation in colon adenocarcinoma cells. Al-
though we didn’t observe any statistical correlation be-
tween CLK1 and nucleus SRSF1 level, both SRPK1 and
SRPK2 indeed correlated with SRSF1 nucleus transloca-
tion. Additionally, SRPK1 and SRPK2 showed upregu-
lated expression in CAC tissues compared with adjacent
tissues, which is consistent with their expression pat-
terns in acute myeloid leukemia, breast cancer, and pan-
creatic cancer [29–31].
In accordance with their underlying crosstalk, SRPK1/
2 and SRSF1 are all identified as independent risk factors
for the overall survival of CAC patients. Following cellu-
lar results again confirmed that silencing SRPK1 and
SRPK2 can lead to decreased SRSF1 phosphorylation,
nucleus transportation, MKNK2a-MKNK2b switch, and
cell proliferation. Similar results were obtained by intro-
ducing kinase-dead mutants or using their inhibitor
SRPIN340. Of note, we systematically verified that both
SRPK1 and SRPK2 can directly interact and phosphoryl-
ate SRSF1 by immunoprecipitation, GST pull-down, and
in vitro phosphorylation test. The anti-tumor effects of
SRPK inhibition had been recently reported in other ma-
lignancies [31, 32], our data enlarged the therapeutic po-
tential of developing SRPK inhibitor for CAC treatment.
Interestingly, a previous study by Wang et al. demon-
strated that SRPK1 can act as both oncogene and tumor
suppressor, either higher or lower level of SRPK1 in-
duces cell transformation [33]. The underlying mechan-
ism is determined by the interaction between SRPK1
and PHLPP, thus aberrant SRPK1 expression in either
direction could result in hyperactivation of Akt by block-
ing its phosphatase PHLPP. Considering that specific ef-
fect of kinase is largely depend on its substrate,
identification of other SRPK1 substrates will be invalu-
able for further illustrating its tumor-related role. Any-
way, here our data confirmed the pro-oncogenic axis of
SRPK1/2-SRSF1-MKNK2 in CAC progression.
Fig. 7 SRPKs and PP1α have opposite effects on MKNK2 alternative splicing and tumor growth in mice model. SW480 cells transduced with
shSRPK1/2, or overexpressing SRPK1&2, or overexpressing PP1α-T320A were subcutaneously injected into six-week male Balb/c nude mice. The
mice condition was monitored from the date of observing macroscopical xenograft. The body weight (a) or food consumption (b) of mice in
each group showed no statistical difference. c Xenograft growth curves were plotted as described in the Method section. The mice were scarified
after monitoring for 20 days, then the xenografts were isolated, weighted (d), and photographed (e). f Levels of MKNK2a and MKNK2b splicing
variants were tested via RT-qPCR from isolated xenografts. g Representative H&E staining and Ki-67 immunostaining results of isolated xenografts.
Scale bar: 100 μm. h The proliferation index was determined using the percentage of Ki-67 positive cells in isolated xenografts. i A schematic
model shows the effects of SRPK1/2 and PP1α on regulating MKNK2a/MKNK2b switch. MKNK2 pre-mRNA can be alternatively spliced into two
MKNK2 mRNA isoforms and further translated into two protein isoforms, namely Mnk2a and Mnk2b. Mnk2a perhaps play an anti-tumor role while
Mnk2b exerts remarkable oncogenic effects according to our data. In nontumorous cells, Mnk2a is the predominantly protein isoform compared
to Mnk2b. In colon adenocarcinoma cells, SRPK1 and SRPK2 are upregulated while PP1α is inactivated, resulting into a hyperphosphorylation
status of SRSF1. Phosphorylation of SRSF1 promotes its nucleus transportation in a TNPO3-dependent manner. The nucleus SRSF1 can directly
bind to MKNK2 pre-mRNA and significantly generate more MKNK2b isoform, while the MKNK2a proportion is decreased
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Besides kinases, we next focused on SRSF1 upstream
phosphatase to impartially evaluate the importance of its
phosphorylation in CAC. Adams JA et.al and her col-
leagues reported that protein phosphatase 1α (PP1α) dir-
ectly dephosphorylates the RS domain of SRSF1 through
binding to its RNA recognition motif 1 (RRM1) through
an allosteric mechanism [34]. Of note, disrupting the
interaction between PP1α and SRSF1 results in signifi-
cant shifts of alternative splicing such as EIF5 and
TIMM8B genes [35]. On the other hand, PP1α has been
demonstrated to inhibit the metastasis of SW620 colon
cancer cells via deactivating Src protein [36]. Therefore,
we were promoted to assess whether PP1α was dysregu-
lated in colon adenocarcinoma. Although we didn’t find
any significant difference of PP1α expression between
CAC tissues and adjacent tissues, its catalytic inactivate
type, namely the Tyr320-phosphorylated PP1α, was ele-
vated in tumor tissues, indicating that PP1α activity was
downregulated in colon adenocarcinoma. Here we also
validated the role of PP1α on regulating MKNK2 alter-
native splicing by introducing its constitutively active
mutant and inactive mutant, respectively. Besides
SW480 and HCT-116 cells, PP1α and its mutations
showed similar effects on the metastatic SW620 cell line,
further highlighting the prognostic value of PP1α-
SRSF1-MNK2 axis in CAC progression. However, we
have to keep in mind that phosphorylation status of SR
proteins can not only modulate their subcellular
localization but also determines the splicing site selec-
tion [37], thus the more detailed effects of SRPKs and
PP1α on alternative splicing need further validation. To-
gether with the findings from xenografts, we concluded
that PP1α can attenuates colon cancer progression at
least partially via antagonizing SRPK1/2-induced SRSF1
phosphorylation and downstream MKNK2a-MKNK2b
splicing shift.
Conclusions
Our study reveals a significant role of SRSF1-guided
MKNK2a-MKNK2b splicing switch in the proliferation
of colon adenocarcinoma, which is determined by SRSF1
phosphorylation and subcellular translocation. The alter-
native splicing of MKNK2 is balanced by SRPK1/2 and
PP1α, thus providing opportunities of therapeutic inter-
vention, such as SRPK inhibitors or PP1α allosteric acti-
vators, in treating malignancies. Additionally, the
subcellular location of SRSF1, expression levels of
SRPK1/2, as well as phosphorylation status of PP1α can
all serve as independent prognostic predictors for the
overall survival of colon adenocarcinoma.
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